A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell Tumor

Inclusion Criteria: * Age ≥ 18 years old. * Part 1: Subjects with solid tumors that are refractory to, relapsed after or intolerant to standard therapy, or for whom no standard therapy exists or who are considered by the investigator to be inappropriate for standard therapy. * Part 2: Subjects with histologically confirmed, locally advanced or refractory TGCT (including metastatic disease) that has been deemed unresectable by an orthopedic surgeon or similar qualified personnel. * Measurable disease by RECIST 1.1 criteria. * Women of child-bearing potential must have a negative pregnancy test within 7 days prior to initiation of dosing and must agree to use an acceptable method of birth control from the time of the negative pregnancy test up to 3 months after the last dose of study drug, Fertile men must also agree to use an acceptable method of birth control while on study drug and up to 3 months after the last dose of study drug. * All associated toxicity from previous or concurrent cancer therapy must be resolved (to ≤ Grade 1 or Baseline) prior to study treatment administration. * Willingness and ability to provide written informed consent prior to any study-related procedures and comply with all study requirements. * Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2. * Life expectancy ≥ 3 months. * Adequate hematologic, hepatic, and renal function. Exclusion Criteria: * Symptomatic brain metastases. * Investigational drug use within 14 days (or 5 half-l…